The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 27, 2022

Filed:

Aug. 09, 2017
Applicant:

Cytocares (Shanghai) Inc., Shanghai, CN;

Inventors:

Shuai Chen, Shanghai, CN;

Huaxing Zhu, Shanghai, CN;

Yuanping Liao, Shanghai, CN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); C07K 2317/31 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01);
Abstract

This disclosure belongs to the field of biomedical technology, and particularly refers to a trifunctional molecule and the application thereof. The structure of the trifunctional molecule includes a first functional domain, a second functional domain and a third functional domain. These domains are capable of simultaneously binding to CD19, CD3, and T cell positive (negative) costimulatory factors, thereby producing the first and second signal required for T cell activation. The trifunctional molecule is a recombinant protein peptide chain, which can be produced by a eukaryotic cell expression system. The product has a single structure, simple purification process, high protein yield, and preparation process and product stability. The trifunctional molecule is superior to the anti-CD19/anti-CD3 BiTE bispecific antibody in killing CD19-positive target cells. Compared with the CAR-T technology targeting CD19, the trifunctional molecule is more convenient to use, the dose is controllable, and the side effects of CAR-T are avoided.


Find Patent Forward Citations

Loading…